Physician profile
Poornima Saha
NPI 1699063644
$18,371.37
in general payments reported to CMS, 2019-2025
8 companies · $5,542 in 2025
The $5,542 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2021: $11.92 · 2023: $3,910 · 2024: $8,808 · 2025: $5,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $2,700 · Food and Beverage: $378 · Grant: $250 · Education: $31.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,900.00 |
| Consulting Fee | $2,700.00 |
| Food and Beverage | $377.63 |
| Grant | $250.00 |
| Education | $31.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17,989.55 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2024 | |
| Genentech USA, INC. | $100.13 | 2019 | |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Keytruda |
| Pfizer INC. | $11.88 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poornima Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.